Overall these in vitro and in vivo data provided evidence that specific targeting of LSD1, at the H3 allosteric site via SP-2509, can lead to effective upregulation of TSGs and may be a viable therapeutic option for exploiting TBX2 dependency in breast cancers. Here, TBX2 is linked to breast carcinoma.